Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
NCT ID: NCT07260708
Last Updated: 2025-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
42 participants
INTERVENTIONAL
2025-12-16
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TQB2922 injection (subcutaneous injection)
TQB2922 injection (Subcutaneous Injection), 28 days as a treatment cycle
TQB2922 injection (subcutaneous injection)
TQB2922 is a bispecific antibody against Epidermal Growth Factor Receptor (EGFR)/c-Met.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TQB2922 injection (subcutaneous injection)
TQB2922 is a bispecific antibody against Epidermal Growth Factor Receptor (EGFR)/c-Met.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-75 yeas old；
* Eastern Cooperative Oncology Group Performance Status (ECOG) score: 0-1;
* Expected survival of more than 12 weeks；
* Histologically or cytologically diagnosed with advanced non-squamous non-small cell lung cancer
* Subjects in the monotherapy introduction stage need to have received standard treatment or lack effective treatment.
* There must be at least one measurable lesion within the radiotherapy area that can be clearly classified as progressive according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1) criteria.
* Major organs are functioning well；
* Female and male subjects of childbearing potential should agree to practice contraception for the duration of the study and for 6 months after the end of the study.
Exclusion Criteria
* At the time of initiating the study of treatment, the adverse reactions caused by previous anti-tumor treatments failed to recover to a CTCAE 5.0 score of grade 1 or below.
* Patients who had received major surgical treatment within 4 weeks prior to the first study, had obvious traumatic injuries, or were expected to undergo major surgery during the study treatment period, or had long-term unhealed wounds or fractures.
* Hyperactive or venous thrombosis events occurred within 6 months before the first administration;
* Major cardiovascular diseases;
* Active hepatitis
* Those with a history of psychotropic drug abuse who are unable to quit or have mental disorders.
* There was an active infection (≥ Common Terminology Criteria for Adverse Events version 5.0 (CTCAE5.0) score of grade 2) within 2 weeks before the first administration;
* Patients with renal failure requiring hemodialysis or peritoneal dialysis;
* Patients who have a history of immune deficiency.
* Patients who have epilepsy and need treatment;
* Evidence of a previous history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any clinically active interstitial lung disease.
* Those who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first treatment.
* Pregnant or lactating women.
* There is any serious or uncontrolled systemic disease.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Affiliated Zhongshan Hospital of Dalian University
Dalian, Liaoning, China
Shandong Cancer Hospital
Jinan, Shandong, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
West China hospital, Sichuan University
Chengdu, Sichuan, China
Chengdu Third People's Hospital
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Li Zhang, Doctor
Role: primary
Yanqiu Zhao, Doctor
Role: primary
Sanxing Guo, Doctor
Role: primary
Yongchang Zhang, Doctor
Role: primary
Yongsheng Wang, Doctor
Role: primary
Longhua Sun, Doctor
Role: primary
Jinhua Wen, Doctor
Role: backup
Ruoyu Wang, Doctor
Role: primary
Xiang Li, Master
Role: backup
Linlin Wang, Doctor
Role: primary
Qi Dang, Master
Role: backup
Shengxiang Ren, Doctor
Role: primary
Jianxin Xue, Doctor
Role: primary
Li Zheng, Doctor
Role: backup
Yi Yang, Master
Role: primary
Maozhi Liang, Bachelor
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TQB2922-I-02
Identifier Type: -
Identifier Source: org_study_id